Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Hepatitis C

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 41 articles:
HTML format
Text format

Single Articles

    November 2017
  1. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    PubMed     Text format     Abstract available

    July 2017
  2. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed     Text format    

    June 2017
  3. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Text format     Abstract available

  4. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Text format     Abstract available

  5. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Text format     Abstract available

  6. ARRIAZU E, Ge X, Leung TM, Magdaleno F, et al
    Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.
    Gut. 2017;66:1123-1137.
    PubMed     Text format     Abstract available

    March 2017
  7. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Text format     Abstract available

  8. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed     Text format    

    February 2017
  9. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available

    January 2017
  10. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    

    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    PubMed     Text format    

    December 2016

  12. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    PubMed     Text format    

    November 2016
  13. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    PubMed     Text format    

    October 2016
  14. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    PubMed     Text format     Abstract available

  15. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    PubMed     Text format     Abstract available

    September 2016
  16. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    PubMed     Text format     Abstract available

  17. WELZEL TM, Petersen J, Herzer K, Ferenci P, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016 Sep 7. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444.
    PubMed     Text format     Abstract available

    August 2016
  18. BEILSTEIN F, Lemasson M, Pene V, Rainteau D, et al
    Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
    Gut. 2016 Aug 31. pii: gutjnl-2016-311508. doi: 10.1136/gutjnl-2016-311508.
    PubMed     Text format     Abstract available

  19. HUTIN YJ, Wiktor SZ
    Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
    Gut. 2016 Aug 26. pii: gutjnl-2016-312636. doi: 10.1136/gutjnl-2016-312636.
    PubMed     Text format    

  20. EL-KHAYAT HR, Fouad YM, Maher M, El-Amin H, et al
    Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
    Gut. 2016 Aug 10. pii: gutjnl-2016-312012. doi: 10.1136/gutjnl-2016-312012.
    PubMed     Text format     Abstract available

    July 2016
  21. LIU CH, Lin CC, Hsu WC, Chung CY, et al
    Highly bioavailable silibinin nanoparticles inhibit HCV infection.
    Gut. 2016 Jul 19. pii: gutjnl-2016-312019. doi: 10.1136/gutjnl-2016-312019.
    PubMed     Text format     Abstract available

  22. WELZEL TM, Nelson DR, Morelli G, Di Bisceglie A, et al
    Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609.
    PubMed     Text format     Abstract available

  23. SHIMAKAWA Y, Bonnard P, El Kassas M, Abdel-Hamid M, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4.
    Gut. 2016 Jul 7. pii: gutjnl-2016-312326. doi: 10.1136/gutjnl-2016-312326.
    PubMed     Text format    

    June 2016
  24. GOUTTENOIRE J, Szkolnicka D, Moradpour D
    Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut. 2016 Jun 22. pii: gutjnl-2016-312040. doi: 10.1136/gutjnl-2016-312040.
    PubMed     Text format    

    April 2016
  25. FISCHER J, Weber AN, Bohm S, Dickhofer S, et al
    Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
    Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239.
    PubMed     Text format     Abstract available

  26. SCOTT N, McBryde ES, Thompson A, Doyle JS, et al
    Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Gut. 2016 Apr 12. pii: gutjnl-2016-311504. doi: 10.1136/gutjnl-2016-311504.
    PubMed     Text format     Abstract available

    February 2016
  27. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    PubMed     Text format     Abstract available

    January 2016
  28. SERTI E, Park H, Keane M, O'Keefe AC, et al
    Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha.
    Gut. 2016 Jan 4. pii: gutjnl-2015-310033. doi: 10.1136/gutjnl-2015-310033.
    PubMed     Text format     Abstract available

    December 2015
  29. VARCHETTA S, Mele D, Lombardi A, Oliviero B, et al
    Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.
    Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327.
    PubMed     Text format     Abstract available

    November 2015
  30. PRENTOE J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, et al
    HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.
    Gut. 2015 Nov 20. pii: gutjnl-2015-310300. doi: 10.1136/gutjnl-2015-310300.
    PubMed     Text format     Abstract available

  31. ZOULIM F, Liang TJ, Gerbes AL, Aghemo A, et al
    Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
    Gut. 2015;64:1824-33.
    PubMed     Text format     Abstract available

    October 2015
  32. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    PubMed     Text format     Abstract available

    August 2015
  33. VERCAUTEREN K, Brown RJ, Mesalam AA, Doerrbecker J, et al
    Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Gut. 2015 Aug 25. pii: gutjnl-2014-309045. doi: 10.1136/gutjnl-2014-309045.
    PubMed     Text format     Abstract available

  34. STOHR S, Costa R, Sandmann L, Westhaus S, et al
    Host cell mTORC1 is required for HCV RNA replication.
    Gut. 2015 Aug 14. pii: gutjnl-2014-308971. doi: 10.1136/gutjnl-2014-308971.
    PubMed     Text format     Abstract available

  35. DEUFFIC-BURBAN S, Yazdanpanah Y
    Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.
    Gut. 2015;64:1190-1.
    PubMed     Text format    

    July 2015
  36. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Text format     Abstract available

    June 2015
  37. MAJOR ME
    Hepatitis C: new clues to better vaccines?
    Gut. 2015 Jun 19. pii: gutjnl-2015-309829. doi: 10.1136/gutjnl-2015-309829.
    PubMed     Text format    

  38. VON DELFT A, Humphreys IS, Brown A, Pfafferott K, et al
    The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
    Gut. 2015 Jun 19. pii: gutjnl-2014-308724. doi: 10.1136/gutjnl-2014-308724.
    PubMed     Text format     Abstract available

  39. TESTONI B, Durantel D, Lebosse F, Fresquet J, et al
    Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
    Gut. 2015 Jun 16. pii: gutjnl-2014-309011. doi: 10.1136/gutjnl-2014-309011.
    PubMed     Text format     Abstract available

  40. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Text format     Abstract available

    July 2014
  41. ARNDT S, Wacker E, Dorn C, Koch A, et al
    Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
    Gut. 2014 Jul 10. pii: gutjnl-2014-306968. doi: 10.1136/gutjnl-2014-306968.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.